| Up
2006P-0122:
ANDA Suitability for Cetirizine Hydrochloride Orally
Disintegrating Tablets, 5 mg and 10 mg
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Document #
|
| Received Date
|
| Filed
Date
|
| Submitter Code
|
| Submitter
|
| FR
Date
|
| FR
Page
|
| Comment Date
|
| Files
|
| Remarks
|
|
|
|
|
|
|
| CP1
|
| 03/17/2006
|
| 03/17/2006
|
| Private Industry
|
| Lachman Consultant
Services, Inc.
|
|
|
|
|
|
|
| Table
of Contents
|
|
|
|
|
| Signature:
|
| Joan Janulis, Director
|
|
|
|
|
| ACK1
|
| 03/17/2006
|
| 03/17/2006
|
| Federal Government
|
| HFA-305 to Lachman
Consultant Services, Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
|
| Signature:
|
| Jennie C. Butler
|
|
Top | Up
Page last updated
May 15, 2006
kk
Dockets Home Page | Dockets
Contacts and Location | Operating
Status | Item
Code Definitions | Federal
Register
FDA Home Page | Search
FDA Site | FDA A-Z Index
| Contact FDA
FDA/Dockets Management |
